Showing 4221-4230 of 6036 results for "".
- Eversight Partners with Emmecell Biotech to Advance Ocular Cell Therapieshttps://modernod.com/news/eversight-partners-with-emmecell-biotech-to-advance-ocular-cell-therapies/2482124/Global nonprofit eye bank Eversight has partnered with biotech company Emmecell to advance cell therapies for the treatment of eye disease. Financial terms of the deal were not disclosed. Emmecell’s minimally invasive cell therapy injects healthy corneal
- RetinAI Launches Discovery Platform for Ophthalmology and Optometry Clinicshttps://modernod.com/news/retinai-discovery-platform-launched-to-improve-workflows-referrals-and-patient-management-in-ophthalmology-and-optometry-clinics/2482122/Ikerian, the parent company of RetinAI, announced the launch of 'RetinAI Discovery for Clinics,' which features AI models designed to accelerate and enhance clinical decision workflows, teleophthalmology management, referral decisions, and patient manage
- Johnson & Johnson Launches Tecnis PureSee Presbyopia-Correcting IOL in EMEAhttps://modernod.com/news/johnson-johnson-launches-tecnis-puresee-presbyopia-correcting-iol-in-emea/2482116/Johnson & Johnson MedTech announced that its Tecnis PureSee presbyopia-correcting IOL is now available in Europe, the Middle East, and Africa (EMEA). The Tecnis PureSee IOL features a proprietary, purely refractive design that delivers uninterrupted, high-quality, vision with high best-in-cat
- Ocular Therapeutix Announces First Subjects Screened in Phase 3 Clinical Trial of Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-first-subjects-screened-in-phase-3-pivotal-clinical-trial-of-axpaxli-in-wet-amd/2482113/Ocular Therapeutix announced that the first three subjects have been screened and received their first aflibercept injection in the phase 3 SOL-1 clinical trial of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related macular degenerati
- EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restorethttps://modernod.com/news/eyebio-announces-positive-visual-anatomic-and-safety-data-from-first-in-human-ph1b2a-amarone-trial-of-restoret/2482112/Eyebiotech announced the presentation of Week 12 data from its first-in-human phase 1b/2a AMARONE trial of Restoret in patients with treatment-naïve diabetic macular edema (DME) and treatment-naïve wet age-related macular degeneration (AMD). The analysis was presented by Charles C.
- Sylentis Fails Phase 3 Trial of RNAi-based Drug Candidate for Dry Eye Associated with Sjögren's Syndromehttps://modernod.com/news/sylentis-fails-phase-3-trial-of-rnai-based-drug-candidate-for-dry-eye-associated-with-sjogrens-syndrome/2482110/Sylentis, a subsidiary of Spain-based PharmaMar, announced that its phase 3 SYL10111_V (RNAi-based tivanisiran) clinical trial for the treatment of dry eye disease associated with Sjögren’s syndrome did not meet its primary endpoint—the signs and symptoms of DED. T
- Adverum Announces Positive Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDhttps://modernod.com/news/adverum-biotechnologies-announces-positive-preliminary-efficacy-and-safety-data-from-luna-phase-2-trial-of-ixo-vec-in-patients-with-wet-amd/2482107/Adverum Biotechnologies announced preliminary safety and efficacy data from the ongoing LUNA phase 2 trial in patients with wet age-related macular degeneration (AMD). These data are being presented by Arshad Khanani, MD, today at the 47th Annual Meeting of the Macula Society. The presentation, t
- Shamir Launches Spark 4W Digital Electro-Optic Measurement Systemhttps://modernod.com/news/shamir-launches-spark-4w-digital-electro-optic-measurement-system/2482101/Shamir announced the launch of the Spark 4W, a digital electro-optic measurement system based on 3D stereo vision technology and artificial intelligence (AI) elements. Shamir Spark 4W is designed to enable eye care professionals (ECPs) to obtain precise and automatic meas
- 4D Molecular Therapeutics' Gene Therapy Maintains Stable Visual Acuity in Wet AMD Patients in Phase 2 Studyhttps://modernod.com/news/new-data-shows-4d-molecular-therapeutics-gene-therapy-cuts-eylea-use-in-wet-amd-patients/2482097/4D Molecular Therapeutics announced positive interim data from the phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (AMD) patients with severe disease activity and a high treatment burden. Data presented at the Angiogenesis, Exudat
- Aviceda Announces First Patient Dosed in Part 2 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for GAhttps://modernod.com/news/aviceda-therapeutics-announces-first-patient-dosed-in-part-2-of-the-phase-23-siglec-trial-assessing-avd-104-for-ga/2482092/Aviceda Therapeutics announced it has dosed the first patient in part 2 of the phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “Based on the efficacy and safety we saw in part 1, we moved rapidly to i